New concepts on the immune modulation mediated by mesenchymal stem cells

Stem Cell Research and Therapy

Volumn 1, Issue 5, 2010, Pages

  Bunnell, Bruce A ^a,b   Betancourt, Aline M ^a   Sullivan, Deborah E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; INDOLEAMINE 2,3 DIOXYGENASE; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

CELL ACTIVITY; CELL DIFFERENTIATION; CELL POLARITY; CYTOKINE PRODUCTION; CYTOLOGY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; INFLAMMATION; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; INFLAMMATION; INFLAMMATION MEDIATORS; MESENCHYMAL STROMAL CELLS;

EID: 80052422003     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt34     Document Type: Review

References (88)

1. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV, Transplantation 1974 17 331 340 10.1097/00007890-197404000-00001 4150881
2. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA, Exp Hematol 1974 2 83 92 4455512
3. Mesenchymal stem cells: revisiting history, concepts, and assays. Bianco P, Robey PG, Simmons PJ, Cell Stem Cell 2008 2 313 319 10.1016/j.stem.2008.03. 002 18397751 (Pubitemid 351467394)
4. Marrow stromal cells as stem cells for nonhematopoietic tissues. Prockop DJ, Science 1997 276 71 74 10.1126/science.276.5309.71 9082988 (Pubitemid 27161245)
5. Mesenchymal stem cells in health and disease. Uccelli A, Moretta L, Pistoia V, Nat Rev Immunol 2008 8 726 736 10.1038/nri2395 19172693
6. Marrow stromal cell transplantation in stroke and traumatic brain injury. Li Y, Chopp M, Neurosci Lett 2009 456 120 123 10.1016/j.neulet.2008.03.096 19429146
7. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Prockop DJ, Olson SD, Blood 2007 109 3147 3151 10.1182/blood-2006-03-013433 17170129 (Pubitemid 46572498)
8. Transplantation of bone marrow-derived stem cells: a promising therapy for stroke. Tang Y, Yasuhara T, Hara K, Matsukawa N, Maki M, Yu G, Xu L, Hess DC, Borlongan CV, Cell Transplant 2007 16 159 169 17474297 (Pubitemid 46668790)
9. Mesenchymal stem cells as trophic mediators. Caplan AI, Dennis JE, J Cell Biochem 2006 98 1076 1084 10.1002/jcb.20886 16619257 (Pubitemid 44128350)
10. Why are MSCs therapeutic? New data: new insight. Caplan AI, J Pathol 2009 217 318 324 10.1002/path.2469 19023885
11. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. Chen L, Tredget EE, Wu PY, Wu Y, PLoS One 2008 3 1886 10.1371/journal.pone.0001886 18382669 (Pubitemid 351943822)
12. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Hocking AM, Gibran NS, Exp Cell Res 2010 316 2213 2219 10.1016/j.yexcr.2010.05.009 20471978
13. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI, Cytokine Growth Factor Rev 2009 20 419 427 10.1016/j.cytogfr.2009.10.002 19926330
14. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Prockop DJ, Mol Ther 2009 17 939 946 10.1038/mt.2009.62 19337235
15. New era of cell-based orthopedic therapies. Caplan AI, Tissue Eng Part B Rev 2009 15 195 200 10.1089/ten.teb.2008.0515 19228082
16. Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S, Pittenger MF, Blood 2005 105 1815 1822 10.1182/blood-2004-04-1559 15494428 (Pubitemid 40223708)
17. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Jones BJ, McTaggart SJ, Exp Hematol 2008 36 733 741 10.1016/j.exphem.2008.03.006 18474304 (Pubitemid 351636190)
18. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lonnies H, Nava S, Ringden O, Leukemia 2007 21 1733 1738 10.1038/sj.leu.2404777 17541394 (Pubitemid 47086763)
19. Mesenchymal stromal cells: current understanding and clinical status. Salem HK, Thiemermann C, Stem Cells 2010 28 585 596 19967788
20. Immune regulation by mesenchymal stem cells: two sides to the coin. Stagg J, Tissue Antigens 2007 69 1 9 10.1111/j.1399-0039.2006.00739.x 17212702
21. Immunoregulatory function of mesenchymal stem cells. Uccelli A, Moretta L, Pistoia V, Eur J Immunol 2006 36 2566 2573 10.1002/eji.200636416 17013987 (Pubitemid 44608440)
22. Mesenchymal stem cells: a new strategy for immunosuppression? Uccelli A, Pistoia V, Moretta L, Trends Immunol 2007 28 219 226 10.1016/j.it.2007.03.001 17400510 (Pubitemid 46667240)
23. Is there a role for mesenchymal stem cells in autoimmune diseases? Uccelli A, Mancardi G, Chiesa S, Autoimmunity 2008 41 592 595 10.1080/08916930802200166 18958745
24. Role of toll-like receptors on human adiposederived stromal cells. Hwa Cho H, Bae YC, Jung JS, Stem Cells 2006 24 2744 2752 10.1634/stemcells.2006-0189 16902195 (Pubitemid 46053012)
25. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, Mazzinghi B, Maggi L, Pasini A, Lisi V, Santarlasci V, Consoloni L, Angelotti ML, Romagnani P, Parronchi P, Krampera M, Maggi E, Romagnani S, Annunziato F, Stem Cells 2008 26 279 289 10.1634/stemcells.2007-0454 17962701
26. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Lombardo E, DelaRosa O, Mancheno-Corvo P, Menta R, Ramirez C, Buscher D, Tissue Eng Part A 2009 15 1579 1589 10.1089/ten.tea.2008.0340 19061425
27. Toll-like receptors and their ligands control mesenchymal stem cell functions. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, Cohen IR, Zipori D, Blood 2007 109 1422 1432 10.1182/blood-2006-06-028704 17038530 (Pubitemid 46239573)
28. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB, Stem Cells 2008 26 99 107 10.1634/stemcells.2007- 0563 17916800
29. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM, PLoS One 2010 5 10088 10.1371/journal.pone.0010088 20436665
30. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F, Blood 2003 101 3722 3729 10.1182/blood-2002-07-2104 12506037 (Pubitemid 36857965)
31. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM, Blood 2002 99 3838 3843 10.1182/blood.V99.10.3838 11986244 (Pubitemid 34534559)
32. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC, Transplantation 2003 75 389 397 10.1097/01.TP.0000045055.63901.A9 12589164 (Pubitemid 36222968)
33. Contactdependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Gur-Wahnon D, Borovsky Z, Beyth S, Liebergall M, Rachmilewitz J, Exp Hematol 2007 35 426 433 10.1016/j.exphem.2006.11.001 17309823
34. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E, Nat Med 2009 15 42 49 10.1038/nm.1905 19098906
35. Immunomodulatory properties of mesenchymal stromal cells. Nauta AJ, Fibbe WE, Blood 2007 110 3499 3506 10.1182/blood-2007-02-069716 17664353 (Pubitemid 350159613)
36. Modulation of immune responses by mesenchymal stem cells. Fibbe WE, Nauta AJ, Roelofs H, Ann N Y Acad Sci 2007 1106 272 278 10.1196/annals.1392.025 17442776 (Pubitemid 47443061)
37. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D, Blood 2004 103 4619 4621 10.1182/blood-2003-11-3909 15001472 (Pubitemid 38745993)
38. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Maby-El Hajjami H, Amé-Thomas P, Pangault C, Tribut O, DeVos J, Jean R, Bescher N, Monvoisin C, Dulong J, Lamy T, Fest T, Tarte K, Cancer Res 2009 69 3228 3237 10.1158/0008-5472.CAN-08-3000 19276371
39. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K, Blood 2007 109 228 234 10.1182/blood-2006-02-002246 16985180 (Pubitemid 46053063)
40. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Kong QF, Sun B, Wang GY, Zhai DX, Mu LL, Wang DD, Wang JH, Li R, Li HL, Eur J Immunol 2009 39 800 809 10.1002/eji.200838729 19283707
41. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Ryan JM, Barry F, Murphy JM, Mahon BP, Clin Exp Immunol 2007 149 353 363 10.1111/j.1365-2249.2007.03422.x 17521318 (Pubitemid 47063057)
42. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. English K, Barry FP, Field-Corbett CP, Mahon BP, Immunol Lett 2007 110 91 100 10.1016/j.imlet.2007.04.001 17507101 (Pubitemid 46830943)
43. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F, Stem Cells 2006 24 386 398 10.1634/stemcells.2005-0008 16123384 (Pubitemid 44464808)
44. What are subcutaneous adipocytes really good for? Klein J, Permana PA, Owecki M, Chaldakov GN, Böhm M, Hausman G, Lapiére CM, Atanassova P, Sowiski J, Fasshauer M, Hausman DB, Maquoi E, Tonchev AB, Peneva VN, Vlachanov KP, Fiore M, Aloe L, Slominski A, Reardon CL, Ryan TJ, Pond CM, Ryan TJ, Exp Dermatol 2007 16 45 70 17181636
45. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M, Stem Cells 2009 27 909 919 10.1002/stem.7 19353519
46. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Ren G, Su J, Zhang L, Zhao X, Ling W, L'huillie A, Zhang J, Lu Y, Roberts AI, Ji W, Zhang H, Rabson AB, Shi Y, Stem Cells 2009 27 1954 1962 10.1002/stem.118 19544427
47. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Chen K, Wang D, Du WT, Han ZB, Ren H, Chi Y, Yang SG, Zhu D, Bayard F, Han ZC, Clin Immunol 2010 135 448 458 10.1016/j.clim.2010.01.015 20207200
48. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Prigione I, Benvenuto F, Bocca P, Battistini L, Uccelli A, Pistoia V, Stem Cells 2009 27 693 702 10.1634/stemcells.2008-0687 19096038
49. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells. Martinet L, Fleury-Cappellesso S, Gadelorge M, Dietrich G, Bourin P, Fournie JJ, Poupot R, Eur J Immunol 2009 39 752 762 10.1002/eji.200838812 19197941
50. Interactions between human mesenchymal stem cells and natural killer cells. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M, Stem Cells 2006 24 74 85 10.1634/stemcells.2004-0359 16099998
51. MSCs inhibit monocytederived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L, Blood 2009 113 6576 6583 10.1182/blood-2009-02-203943 19398717
52. Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells. Wehner R, Wehrum D, Bornhauser M, Zhao S, Schakel K, Bachmann MP, Platzbecker U, Ehninger G, Rieber EP, Schmitz M, Haematologica 2009 94 1151 1156 10.3324/haematol.2008.001735 19546436
53. Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. Nemeth K, Mayer B, Mezey E, J Mol Med 2009 88 5 10 10.1007/s00109-009-0523-7 19756450
54. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzon IM, Nepomnaschy I, Costa H, Canones C, Raiden S, Vermeulen M, Geffner JR, PLoS One 2010 5 9252 10.1371/journal.pone.0009252 20169081
55. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Xu G, Zhang L, Ren G, Yuan Z, Zhang Y, Zhao RC, Shi Y, Cell Res 2007 17 240 248 17325691 (Pubitemid 46438724)
56. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG, Hodges MG, Jelinek I, Madala S, Karpati S, Mezey E, Proc Natl Acad Sci USA 2010 107 5652 5657 10.1073/pnas.0910720107 20231466
57. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P, J Immunol 184 5885 5894 10.4049/jimmunol.0903143 20382885
58. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F, Transplantation 2009 87 62 66 10.1097/TP.0b013e3181a2a4b3 19424010
59. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells. Kang JW, Kang KS, Koo HC, Park JR, Choi EW, Park YH, Stem Cells Dev 2008 17 681 693 10.1089/scd.2007.0153 18717642
60. Mesenchymal cells recruit and regulate T regulatory cells. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, Sportoletti P, Falzetti F, Tabilio A, Exp Hematol 2008 36 309 318 10.1016/j.exphem.2007.11.007 18279718 (Pubitemid 351221170)
61. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Nasef A, Mazurier C, Bouchet S, Francois S, Chapel A, Thierry D, Gorin NC, Fouillard L, Cell Immunol 2008 253 16 22 10.1016/j.cellimm.2008.06.002 18639869
62. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Volarevic V, Al-Qahtani A, Arsenijevic N, Pajovic S, Lukic ML, Autoimmunity 2010 43 255 263 10.3109/08916930903305641
63. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG, Proc Natl Acad Sci USA 2007 104 11002 11007 10.1073/pnas.0704421104 17569781 (Pubitemid 47175216)
64. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, Forner K, Boivin MN, Doody K, Tremblay M, Annabi B, Galipeau J, Blood 2008 112 4991 4998 10.1182/blood-2008- 07-166892 18812467
65. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Lepelletier Y, Lecourt S, Renand A, Arnulf B, Vanneaux V, Fermand JP, Menasche P, Domet T, Marolleau JP, Hermine O, Larghero J, Stem Cells Dev 2010 19 1075 1079 10.1089/scd.2009. 0212 19886821
66. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Sioud M, Mobergslien A, Boudabous A, Floisand Y, Scand J Immunol 2010 71 267 274 10.1111/j.1365-3083. 2010.02378.x 20384870
67. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ, Cell Stem Cell 2009 5 54 63 10.1016/j.stem.2009.05. 003 19570514
68. TSG-6 potentiates the antitissue kallikrein activity of inter-alphainhibitor through bikunin release. Forteza R, Casalino-Matsuda SM, Monzon ME, Fries E, Rugg MS, Milner CM, Day AJ, Am J Respir Cell Mol Biol 2007 36 20 31 10.1165/rcmb.2006-0018OC 16873769 (Pubitemid 46067704)
69. The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha -inhibitor-independent manner. Getting SJ, Mahoney DJ, Cao T, Rugg MS, Fries E, Milner CM, Perretti M, Day AJ, J Biol Chem 2002 277 51068 51076 10.1074/jbc.M205121200 12401803 (Pubitemid 36042279)
70. TSG-6: a pluripotent inflammatory mediator? Milner CM, Higman VA, Day AJ, Biochem Soc Trans 2006 34 446 450 10.1042/BST0341261 16709183 (Pubitemid 46769034)
71. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. Wisniewski HG, Vilcek J, Cytokine Growth Factor Rev 2004 15 129 146 10.1016/j.cytogfr.2004.01.005 15110797 (Pubitemid 38521249)
72. Signaling danger: toll-like receptors and their potential roles in kidney disease. Anders HJ, Banas B, Schlondorff D, J Am Soc Nephrol 2004 15 854 867 10.1097/01.ASN.0000121781.89599.16 15034087 (Pubitemid 38375304)
73. New insights into the regulation of TLR signaling. Miggin SM, O'Neill LA, J Leukoc Biol 2006 80 220 226 10.1189/jlb.1105672 16698941 (Pubitemid 44835495)
74. Toll-like receptors in health and disease: complex questions remain. Sabroe I, Read RC, Whyte MK, Dockrell DH, Vogel SN, Dower SK, J Immunol 2003 171 1630 1635 12902458 (Pubitemid 36966443)
75. Recognition and signaling by toll-like receptors. West AP, Koblansky AA, Ghosh S, Annu Rev Cell Dev Biol 2006 22 409 437 10.1146/annurev.cellbio.21. 122303.115827 16822173
76. Toll, a new piece in the puzzle of innate immunity. Wright SD, J Exp Med 1999 189 605 609 10.1084/jem.189.4.605 9989974 (Pubitemid 29193360)
77. A CD14-independent LPS receptor cluster. Triantafilou K, Triantafilou M, Dedrick RL, Nat Immunol 2001 2 338 345 10.1038/86342 11276205 (Pubitemid 33706345)
78. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. Mempel M, Voelcker V, Köllisch G, Plank C, Rad R, Gerhard M, Schnopp C, Fraunberger P, Walli AK, Ring J, Abeck D, Ollert M, J Invest Dermatol 2003 121 1389 1396 10.1111/j.1523-1747.2003.12630.x 14675188 (Pubitemid 38005491)
79. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S, Takatsu K, Kincade PW, Immunity 2006 24 801 812 10.1016/j.immuni.2006. 04.008 16782035 (Pubitemid 43867369)
80. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J, Blood 2005 105 2214 2219 10.1182/blood-2004-07-2921 15514012 (Pubitemid 40731815)
81. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. Romieu-Mourez R, Francois M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J, J Immunol 2009 182 7963 7973 10.4049/jimmunol.0803864 19494321
82. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Raicevic G, Rouas R, Najar M, Stordeur P, Boufker HI, Bron D, Martiat P, Goldman M, Nevessignsky MT, Lagneaux L, Hum Immunol 2010 71 235 244 10.1016/j.humimm.2009.12.005 20034529
83. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH, J Leukoc Biol 2006 79 285 293 10.1189/jlb.0105015 16330536 (Pubitemid 44831160)
84. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. Martinez FO, Gordon S, Locati M, Mantovani A, J Immunol 2006 177 7303 7311 17082649 (Pubitemid 44715100)
85. Trophic macrophages in development and disease. Pollard JW, Nat Rev Immunol 2009 9 259 270 10.1038/nri2528 19282852
86. Prolonged exposure to bacterial toxins downregulated expression of toll-like receptors in mesenchymal stromal cell-derived osteoprogenitors. Mo IF, Yip KH, Chan WK, Law HK, Lau YL, Chan GC, BMC Cell Biol 2008 9 52 10.1186/1471-2121-9-52 18799018
87. Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress-induced apoptosis and enhance proliferation of MSCs via Toll-like receptor(TLR)-4 and PI3K/Akt. Wang ZJ, Zhang FM, Wang LS, Yao YW, Zhao Q, Gao X, Cell Biol Int 2009 33 665 674 10.1016/j.cellbi.2009.03.006 19376254
88. Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. Yao Y, Zhang F, Wang L, Zhang G, Wang Z, Chen J, Gao X, J Biomed Sci 2009 16 74 10.1186/1423-0127-16-74 19691857